伊立替康
医学
肉瘤
替莫唑胺
尤因肉瘤
地铁列车时刻表
肿瘤科
内科学
外科
化疗
癌症
病理
结直肠癌
计算机科学
操作系统
作者
Emily K. Slotkin,Paul A. Meyers
摘要
Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy. Optimal dose schedules have not been defined. We reviewed published series of patients treated with irinotecan and temozolomide for Ewing sarcoma that recurred after initial therapy. We compared objective response rates for patients who received 5-day irinotecan treatment schedules to response rates for patients who achieved 10-day irinotecan treatment schedules. Among 89 patients treated with a 10-day irinotecan schedule, there were 47 objective responses (53%). Among 180 patients treated with a 5-day irinotecan schedule, there were 52 responses (29%). In the treatment of recurrent Ewing sarcoma, investigators should consider the use of a 10-day schedule for administration of irinotecan.
科研通智能强力驱动
Strongly Powered by AbleSci AI